Efficacy and Safety of DLBS1033 in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus Clinical Trial

Official title:

DLBS1033 Therapy in Improving Hypercoagulation State in Subjects With Type 2 Diabetes Mellitus

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01865474
• Other study ID #: DLBS1033-0212
• Status: Completed
• Phase: Phase 4
• First received: May 28, 2013
• Last updated: August 3, 2016
• Start date: May 2013
• Est. completion date: June 2016

Study information

• Verified date: August 2016
• Source: Dexa Medica Group
• Contact: n/a
• Is FDA regulated: No
• Health authority: Indonesia: National Agency of Drug and Food Control
• Study type: Interventional

Clinical Trial Summary

This is a prospective, double-blind, randomized, and controlled study. The investigational product, DLBS1033 at a dose of 490 mg thrice daily or placebo, will be given for an 8-week course of therapy.

DLBS1033 effectively demonstrated fibrinolytic, fibrinogenolytic as well as antithrombotic activities. Hypercoagulation state with high fibrinogen level is usually found in diabetes mellitus patients.

Therefore, the hypothesis of interest of this study is that DLBS1033 will reduce fibrinogen level of diabetes mellitus patients better than that of the Control Group.

Description:

There will be 2 groups of treatment, each consisting of 68 subjects, with the treatment regimens as the following:

Treatment I : DLBS1033 bioactive fraction tablet @ 490 mg, three times daily. Treatment II :

Placebo tablet of DLBS1033, three times daily.

Clinical examination to evaluate the efficacy of the investigational drug will be performed at baseline and every follow-up visit (at interval of 4 weeks) over the 8 weeks of study period. All subjects will be advised to follow such a lifestyle modification throughout the study period.

All subjects will be under direct supervision of a medical doctor during the study period.

During the study period, anti-diabetes treatment taken by study subjects should still be continued. Other treatment related to subjects' concomitant illnesses, such as hypertension, and/or dyslipidemia, is allowed during subjects' participation in the study.

Other medication such as anti-platelets, fibrinolytic agents and anti-coagulants, or other treatment including herbals/alternatives which may affect haemostatic system, are not allowed to be used during the study period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 122
• Est. completion date: June 2016
• Est. primary completion date: June 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 25 Years to 65 Years

Eligibility

Inclusion Criteria:

• Diagnosed as type 2 diabetes mellitus with A1c > 7.0% at Screening.

• Men or women, between 25-65 years of age.

• Have been being treated with lifestyle intervention and/or any oral anti-diabetic agents and/or insulin.

• Adequate liver function: ALT and AST = 2.5 times upper limit of normal.

• Adequate renal function: serum creatinine < 2.0 times upper limit of normal.

• Able to take oral medication.

Exclusion Criteria:

1. For females of childbearing potential: Pregnancy, breast-feeding, the intention of becoming pregnant.

• Patients must accept pregnancy tests during the trial if menstrual cycle is missed.

• Fertile patients must use a reliable and effective contraceptive.

2. The presence of clinically significant electrocardiographic abnormality

3. History of acute coronary syndrome (myocardial infarction, stroke, unstable angina pectoris), peripheral arterial diseases, venous thromboembolism or other cardiovascular events.

4. History of other arteriosclerotic disease necessitating medical or pharmacological treatment.

5. Severe hypertension (systolic blood pressure = 180 mm Hg, diastolic = 110 mm Hg).

6. Treatment with antiplatelets or antithrombotic agents, including other oral lumbrokinase products within 14 days prior to Screening.

7. Subjects with prior experience with DLBS1033.

8. Subjects with high-risk of bleeding

9. Presence of malignancies as observed clinically or by anamnesis.

10. Subjects with any other disease state, including chronic or acute systemic infections, or uncontrolled illnesses, which judged by the investigator, could interfere with trial participation or trial evaluation.

11. Subjects with known or suspected allergy to study medication or similar products.

12. Subjects with concurrent herbal (alternative) medicines or food supplements suspected to have effect on the primary efficacy endpoint.

13. Subjects enrolled in another experimental (interventional) protocol within the past 30 days prior to Screening.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Type 2 Diabetes Mellitus

Intervention

Drug:
• DLBS1033
1 DLBS1033 tablet 490 mg thrice daily for 2 months
• placebo tablet of DLBS1033
1 placebo tablet of DLBS1033 thrice daily for 2 months

Locations

Country	Name	City	State
Indonesia	Department of Internal Medicine, Faculty of Medicine, University of Andalas/ dr. M. Djamil Padang Hospital	Padang	Sumatera Barat

Sponsors (1)

Lead Sponsor	Collaborator
Dexa Medica Group

Country where clinical trial is conducted

Indonesia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fibrinogen level reduction	Fibrinogen level reduction from baseline to the end of study (Week 8th)	8 weeks	No
Secondary	Change of D-dimer	Change of D-dimer from baseline to every follow-up visit	4 weeks and 8 weeks	No
Secondary	Change of von Willebrand Factor activity	Change of von Willebrand Factor activity from baseline to every follow-up visit.	4 weeks and 8 weeks	No
Secondary	Change of hs-CRP level	Change of hs-CRP level from baseline to every follow-up visit.	4 weeks and 8 weeks	No
Secondary	Change of HbA1c	Change of HbA1c from baseline to end of study (Week 8th).	8 weeks	No
Secondary	Liver function	Liver function (serum ALT, AST,?-glutamyl transferase, alkaline phosphatase) at baseline and end of study (Week 8th)	8 weeks	Yes
Secondary	Renal function	Renal function (serum creatinine, BUN) at baseline and end of study (Week 8th)	8 weeks	Yes
Secondary	Prothrombin Time (PT)	Prothrombin time from baseline to every follow-up visit	4 weeks and 8 weeks	Yes
Secondary	Activated partial thromboplastin time (aPTT)	Activated partial thromboplastin time (aPTT)from baseline to every follow-up visit	4 weeks and 8 weeks	Yes
Secondary	Adverse events	Adverse events (mainly: GI bleeding, and other bleeding events) from baseline to every follow-up visit	4 weeks and 8 weeks (during 8 weeks)	Yes
Secondary	Change of Thromboxane-B2 level	Change of Thromboxane-B2 level from baseline to every follow-up visit (as an indirect indicator to assess the effect of study treatment on TxA2)	4 weeks and 8 weeks	No